Europe Protein Therapeutics Market

Europe Protein Therapeutics Market Size

The size of the Europe protein therapeutics market was valued at USD 48.02 billion in 2025. This market is expected to grow at a CAGR of 6.30% from 2026 to 2034, reaching USD 83.22 billion by 2034 from USD 51.05 billion in 2026.

Protein therapeutics are biologically derived molecules, specifically engineered proteins, used as pharmaceutical treatments to prevent, manage, or cure diseases. In Europe, these agents are integral to treating complex chronic conditions such as cancer, autoimmune disorders, and rare genetic diseases, where small-molecule drugs offer limited efficacy. The European regulatory framework under the European Medicines Agency ensures rigorous quality control through guidelines on comparability, immunogenicity, and post-marketing surveillance specific to biological products. Many individuals across Europe are affected by chronic inflammatory and autoimmune disorders, which are seeing an increased reliance on therapeutic proteins for long-term management. The European Union, through its primary health research partnership, has committed substantial funding to accelerate the development of next-generation medical treatments and innovative protein-based therapies. Furthermore, recent regulatory approvals for cancer treatments in Europe reflect a major shift toward therapeutic proteins, which now represent a core component of modern oncological care. This convergence of unmet medical need scientific advancement, and institutional support defines Europe’s pivotal role in the global protein therapeutics landscape.

MARKET DRIVERS

Rising Prevalence of Chronic Immune-Mediated and Oncologic Diseases

The escalating burden of immune-mediated inflammatory diseases and cancers across the region is a primary growth enabler of the Europe protein therapeutics market. A significant, growing population in Europe suffering from chronic inflammatory conditions is increasingly treated with protein-based biologic therapies. Similarly, the European Commission’s Innovative Health Initiative has committed a substantial multi-billion euro budget to advance advanced therapy medicinal products, including engineered proteins. Furthermore, data indicate that protein therapeutics make up a large, increasing proportion of newly approved cancer drugs in the EU, highlighting their clinical importance. The clinical superiority of protein therapeutics in achieving remission and delaying disease progression has led national health technology assessment bodies, including NICE in the UK and HAS in France, to prioritize them in treatment algorithms. This epidemiological and policy alignment ensures sustained demand for high-value biologics across public and private care settings.

Expansion of Biosimilar Approvals Enhancing Accessibility and Competition

The maturation of the biosimilar ecosystem in the region has significantly broadened access to these therapeutics, which propels the expansion of the Europe protein therapeutics market. Simultaneously, this development has stimulated market dynamism. The European Medicines Agency has authorized a high volume of biosimilars since 2006, with a record number of new approvals in 2024, including key molecules like adalimumab, rituximab, and trastuzumab. Enhanced competition from these approvals has significantly reduced annual treatment costs, increasing patient access to biologics, while in Italy, the introduction of biosimilars has boosted the initiation of biologic therapies. Moreover, the EU’s joint procurement initiatives for hospital-delivered biologics have leveraged volume-based pricing to secure sustainable access. This dual effect of cost containment and expanded indication coverage has transformed biosimilars from mere alternatives into strategic enablers of equitable precision medicine across diverse European socioeconomic contexts.

MARKET RESTRAINTS

Stringent Regulatory Requirements for Manufacturing and Batch Consistency

The production of protein therapeutics in Europe faces exacting regulatory standards that impose significant technical and financial barriers, which hamper the growth of the Europe protein therapeutics market. These barriers are particularly challenging regarding batch-to-batch consistency and process validation. Under the European Medicines Agency's guidelines, manufacturers must demonstrate high similarity in quality by performing extensive analytical characterization, which involves comparing numerous critical quality attributes, including structural and functional properties, against the reference product. Ensuring consistent cell culture conditions in large-scale manufacturing requires sophisticated, often real-time monitoring technologies, which represent a significant capital investment per facility. Any deviation in quality attributes can trigger investigation and potential batch rejection, highlighting the risk of product instability and the necessity of strict manufacturing controls. These requirements disproportionately impact small and medium biotech firms lacking integrated quality by design frameworks, thereby limiting innovation diversity and reinforcing market concentration among established players with legacy infrastructure.

High Treatment Costs and Reimbursement Heterogeneity Across Member States

The upfront cost of novel protein therapeutics remains prohibitively high for many regional healthcare systems, despite biosimilar competition, which hinders the expansion of the Europe protein therapeutics market. This leads to fragmented access and delayed adoption. The European Observatory on Health Systems and Policies indicates that the increasing cost of new monoclonal antibodies and rare disease therapies presents significant financial challenges to the sustainability of European health systems. Reimbursement decisions vary widely, with Germany granting early access through AMNOG negotiations while countries like Greece and Portugal impose strict budget caps or require prior treatment failure with older agents. Reports from pharmaceutical industry stakeholders and European monitoring bodies indicate that a majority of EU member states apply additional access restrictions, such as hospital-only dispensing or mandatory registries, on high-cost biologics and orphan medicines. These disparities not only delay patient access but also complicate multinational clinical trial recruitment and commercial planning. Cost will remain a structural barrier to equitable therapeutic access across the European Union until uniform, value-based pricing mechanisms are established.

MARKET OPPORTUNITIES

Advancement of Next Generation Engineered Proteins with Enhanced Functionality

The region is emerging as a hub for next-generation protein engineering, a factor that creates new opportunities for the Europe protein therapeutics market growth. This field enhances therapeutic precision, half-life, and tissue targeting through Fc modifications, bispecific formats, and antibody-drug conjugates. Researchers are developing conditionally active biologics that target diseased microenvironments to enhance treatment precision and minimize damage to healthy tissue. Bispecific T cell engagers, such as blinatumomab, have shown significant efficacy in inducing complete remission among patients with relapsed or refractory acute lymphoblastic leukemia, particularly in those with detectable minimal residual disease. The European Commission is investing significantly through Horizon Europe in AI-driven protein design and advanced manufacturing technologies to advance biotechnology. Additionally, academic spin-outs such as Bicycle Therapeutics in the UK are pioneering peptide-based protein mimetics with superior tumor penetration. These innovations position Europe at the forefront of functional diversification, moving beyond native protein replication toward intelligent molecular machines tailored to complex pathophysiology.

Integration of Real World Evidence in Regulatory and Reimbursement Decision Making

The systematic incorporation of real-world evidence into European regulatory and health technology assessment processes opens up major possibilities to accelerate adoption and demonstrate long term value of protein therapeutics. This is expected to boost the expansion of the Europe protein therapeutics market. As per the European Medicines Agency’s 2023 framework, real-world data from electronic health records, disease registries, and wearable sensors can supplement randomized trial findings for post-authorization safety and effectiveness studies. Sweden’s national rheumatology database provides a comprehensive longitudinal record of patients receiving specialized treatments, offering insights that help shape the country's healthcare funding and clinical priority standards. Similarly, France’s SNDS national health database facilitated rapid safety signal detection for immune checkpoint inhibitors, leading to updated prescribing protocols within six months of market entry. The EHDEN project has established a unified digital framework across Europe that allows researchers to analyze vast amounts of patient data from different countries simultaneously to find broader health patterns. Manufacturers can build compelling value dossiers that align clinical outcomes with payer priorities by leveraging these assets. This alignment is key to enhancing market access in an era of fiscal scrutiny.

MARKET CHALLENGES

Cold Chain Complexity and Temperature Sensitivity During Distribution

Protein therapeutics are highly susceptible to thermal degradation, which inhibits the growth of the Europe protein therapeutics market. They require uninterrupted cold chain storage between two and eight degrees Celsius from manufacturing to the point of administration. Strict temperature control is required for biologics as excursions outside defined limits, often defined as 2-8°C, can cause protein degradation and immunogenicity. Temperature deviations frequently occur during the last-mile transport of biopharmaceuticals, often caused by inadequate refrigerated vehicles or handling delays, despite regulatory standards for quality assurance in logistics. Cross-border logistics, especially at external EU borders, may face delays due to necessary customs and security inspections, which can temporarily disrupt the cold chain. These vulnerabilities necessitate investment in temperature-monitored packaging, IoT-enabled tracking, and validated contingency protocols, costs that can exceed a portion of total product value for high-margin orphan drugs. Product integrity and patient safety are at risk due to weak links in the cold chain, which will persist until harmonized, mandatory certification is enforced across all tiers.

Workforce Shortage in Specialized Biologics Handling and Administration

A growing skills gap in the region shows the urgent need for training in cold chain management, reconstitution, and adverse event recognition for protein therapeutics, a deficiency that slows down the expansion of the Europe protein therapeutics market. Community pharmacies across Europe continue to face challenges regarding specialized training for handling biologics and biosimilars, with a need for further education on proper storage and administration protocols. Oncology infusion centers in Europe report a significant shortage of specialized nurses trained in managing complex, immune-related adverse events and cytokine release syndrome associated with monoclonal antibody therapies. Specialized training for biologics pharmacovigilance is growing, but dedicated, standardized postgraduate modules remain limited in medical and pharmaceutical curricula across the EU. This human capital deficit not only compromises therapeutic outcomes but also deters prescribers from initiating complex regimens, particularly in resource-constrained regions. The full clinical potential of protein therapeutics will remain unrealized across significant segments of the population. This is due to a lack of coordinated upskilling initiatives under frameworks like the EU Pact for Skills.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Insights

The monoclonal antibodies segment was the largest segment in the Europe protein therapeutics market and occupied a 63.7% share in 2025. The supremacy of the segment is attributed to broad applicability across oncology, autoimmune, and infectious disease indications, where they offer high target specificity and durable clinical responses. Monoclonal antibodies such as trastuzumab, pembrolizumab, and rituximab represent foundational, standard-of-care treatments for HER2-positive breast cancer, melanoma, and specific non-Hodgkin lymphomas, respectively, with significant annual usage in European hospital settings. Anti-TNF agents, including adalimumab and infliximab, are key therapeutic options for managing immune-mediated conditions like rheumatoid arthritis, psoriasis, and Crohn's disease within Europe, as highlighted by European League Against Rheumatism guidelines. The regulatory pathway for biosimilars has further entrenched this class by ensuring cost-effective access; several monoclonal antibody biosimilars are now reimbursed in Germany, France, and Italy. Continuous innovation in Fc engineering and subcutaneous delivery formats enhances convenience and adherence, reinforcing their central role in Europe’s precision medicine ecosystem.

The fusion protein segment is anticipated to witness the fastest CAGR of 11.3% between 2026 and 2034 due to its modular design, which combines functional domains from multiple proteins to enhance efficacy half life or targeting precision. Aflibercept, a VEGF trap fusion used for wet age-related macular degeneration and metastatic colorectal cancer, often allows for longer treatment intervals compared to earlier anti-angiogenics, reducing the necessary injection frequency for many patients, as supported by various clinical studies and real-world registries. Similarly, etanercept, a TNF receptor IgG1 Fc fusion, remains a primary biological treatment for juvenile idiopathic arthritis, with data from the German Paediatric Rheumatology Registry demonstrating high retention and efficacy rates for patients in their first year of treatment. The European Commission's Innovative Health Initiative supports the development of next-generation fusion platforms, including T-cell-engaging bispecifics and albumin-fused cytokines, to advance therapeutic options. These engineered molecules address limitations of native proteins, such as rapid clearance or poor tissue penetration, making them indispensable tools in complex therapeutic landscapes.

By Application Insights

The cancer segment led the Europe protein therapeutics market and captured a 41.8% share in 2025. The leading position of the segment is credited to the centrality of monoclonal antibodies and antibody drug conjugates in modern oncology regimens across solid and hematologic malignancies. According to ESMO guidelines, immunotherapy (PD-1/PD-L1 inhibitors) is recommended as a foundational first-line treatment for metastatic cutaneous melanoma and non-oncogene-addicted metastatic non-small cell lung cancer without actionable mutations. Rituximab-based immunotherapy is recognized as a cornerstone treatment for various B-cell non-Hodgkin lymphomas in European clinical practice. The expansion of companion diagnostics ensures precise patient selection, maximizing response rates and minimizing unnecessary toxicity. National cancer plans in Germany, France, and the UK have prioritized equitable access to biologics through centralized procurement and hospital budget protection mechanisms, further solidifying oncology as the dominant therapeutic domain for protein therapeutics in Europe.

The immunologic disorders segment is likely to experience the fastest CAGR of 10.7% over the forecast period, owing to the rising incidence of autoimmune and inflammatory conditions, coupled with earlier diagnosis and expanded treatment eligibility. The World Health Organization and other health studies indicate that the prevalence of numerous autoimmune and immune-mediated diseases is increasing across the European population, placing a growing strain on health systems. Biosimilar adoption has been transformative. The introduction of biosimilars in Italy has enabled increased uptake of advanced therapies, contributing to a trend of rising biologic initiation rates for inflammatory bowel diseases. Furthermore, novel targeted treatments focusing on IL-23 and JAK pathways are improving outcomes for previously treatment-resistant autoimmune conditions, with studies on guselkumab demonstrating high rates of skin clearance in psoriasis patients. Early intervention strategies endorsed by EULAR now recommend biologic initiation within a few months of diagnosis in high-risk rheumatoid arthritis cases, further accelerating uptake across primary and secondary care settings.

By Therapeutic Modalities Insights

The protein therapeutics with special targeting activity segment held the majority share of 58.2% of the Europe protein therapeutics market in 2025. The prominence of the segment is credited to unparalleled precision in modulating disease pathways while sparing healthy tissues, a critical advantage in oncology and autoimmunity. This category includes monoclonal antibodies, bispecifics, and antibody drug conjugates engineered to bind specific cell surface receptors or tumor antigens with high affinity. Trastuzumab deruxtecan has significantly improved median progression-free survival compared to the physician's choice of chemotherapy in patients with HER2-low metastatic breast cancer, as demonstrated in the DESTINY-Breast04 trial, which evaluated patients with previously treated HER2-low disease. Similarly, blinatumomab, a CD19/CD3 bispecific engager, serves as an effective salvage therapy in relapsed acute lymphoblastic leukemia by achieving significant rates of complete remission, often allowing for subsequent transplantation, as noted in studies like the TOWER trial. The European Medicines Agency continues to use its PRIME scheme to accelerate the development and approval of medicines with significant therapeutic potential, providing enhanced support for agents designed to address unmet medical needs. This modality’s success lies in its convergence of molecular insight, engineering sophistication, and clinical impact, making it the cornerstone of Europe’s advanced therapy strategy.

The protein therapeutics with enzymatic or regulatory activity segment is on the rise and is expected to be the fastest-growing segment in the market by witnessing a CAGR of 12.1% between 2026 and 2034. The swift expansion of the segment is fuelled by its ability to correct underlying metabolic or signaling defects in rare and chronic diseases. Enzyme replacement therapies, such as imiglucerase for Gaucher disease and alglucosidase alfa for Pompe disease, are widely utilized in Europe to improve the quality of life for patients with lysosomal storage disorders. Extended half-life recombinant factors have improved hemophilia care by enabling less frequent prophylactic infusions compared to traditional treatments, allowing patients, particularly those with hemophilia B, to manage their condition with fewer doses per month. Innovations in PEGylation, Fc fusion, and albumin binding have further enhanced pharmacokinetics, enabling subcutaneous administration for enzymes like pegvaliase in phenylketonuria. This therapeutic modality is at the vanguard of European functional protein restoration, with more than forty agents currently in late-stage trials for indications spanning Fabry disease to congenital hyperinsulinism.

COUNTRY LEVEL ANALYSIS

Germany Protein Therapeutics Market Analysis

Germany led the European protein therapeutics landscape and captured a 22.4% share in 2025. The supremacy of the German market is driven by an unparalleled concentration of biotechnology clusters in cities like Munich and Heidelberg, where academic research seamlessly transitions into commercial drug development. German pharmaceutical giants such as Merck KGaA and Bayer continue to invest billions in expanding their biologics production capacities to meet global demand for monoclonal antibodies and recombinant proteins. Recent data indicates that the country hosts over 600 active biotech companies with a specific focus on oncology and immunology therapies, driving a year over year growth in this sector. The government supports this ecosystem through the High Tech Strategy, which provides substantial grants for process development and scale-up of mammalian cell culture technologies. Stringent regulatory oversight by the Paul Ehrlich Institute ensures that all protein-based medicines meet the highest safety standards, fostering trust among international partners. Furthermore, the strong presence of contract development and manufacturing organizations allows smaller innovators to access state of the art facilities without massive capital expenditure. This synergy between industrial might, academic excellence, and supportive policy frameworks solidifies Germany as the primary engine for market expansion and technological advancement in Europe.

United Kingdom Protein Therapeutics Market Analysis

The United Kingdom was the second largest country in the Europe protein therapeutics market and accounted for 18.7% share in 2025. The growth of the country’s market is supported by world-leading capabilities in early-stage discovery and clinical trials, particularly within the Golden Triangle of London, Oxford, and Cambridge. British universities produce a disproportionate number of high-impact publications related to protein engineering and antibody design, which attracts significant venture capital from global investors. The UK is moving away from short-term funding cycles toward guaranteed multi-year investments in core research institutions to prevent industry disinvestment. New regulatory reforms, including 14-day assessment routes for Phase I trials, are significantly reducing setup times to make the UK more competitive against international rivals. The Medicines and Healthcare products Regulatory Agency has implemented agile approval pathways that accelerate the time to market for innovative therapies addressing unmet medical needs. Strong collaboration between the National Health Service and industry partners facilitates rapid patient recruitment for trials, ensuring robust data generation. This dynamic environment of scientific brilliance and regulatory efficiency positions the UK as a critical incubator for next-generation protein medicines.

Switzerland Protein Therapeutics Market Analysis

Switzerland remains a significant market for protein therapeutics despite its small geographic size, due to its role as the global headquarters for major pharmaceutical conglomerates. The market has the presence of industry titans like Roche and Novartis, who drive massive revenue through the sales of blockbuster protein drugs, including Herceptin and Cosentyx. Swiss companies lead the world in research and development intensity, with spending often exceeding 20% of their annual revenue to maintain a pipeline of innovative biologics. The country benefits from a stable political environment and strong intellectual property protections that encourage long-term investment in complex molecule development. Recent statistics reveal that Switzerland exports over 90% of its produced protein therapeutics, making it a net positive contributor to the European trade balance in this sector. The Swissmedic regulatory authority is renowned for its rigorous yet efficient evaluation processes, which often set benchmarks for the European Medicines Agency. Highly skilled workforce availability from institutions like ETH Zurich ensures a steady supply of talent specialized in upstream and downstream processing. This unique combination of corporate power, regulatory excellence, and scientific depth ensures Switzerland remains a dominant force in the high-value segment of the market.

France Protein Therapeutics Market Analysis

France occupies a noteworthy position in the European market owing to a renewed national focus on health sovereignty and biomanufacturing independence. The market status is evolving rapidly as the government launches the France 2030 initiative, which allocates a substantial amount specifically to boost domestic production of biologics and reduce reliance on Asian supply chains. French pharmaceutical leaders like Sanofi are reorienting their strategies to prioritize vaccine and antibody production within national borders, creating new jobs and infrastructure. Confidence in French bioproduction is high, evidenced by multi-billion euro commitments from global leaders to build "evolutive" facilities that can switch between different vaccine and drug technologies. The country boasts a rich history in immunology research, with institutes like the Pasteur Institute continuing to pioneer novel therapeutic targets for infectious diseases and autoimmune disorders. Public-private partnerships are flourishing as regional authorities offer tax incentives to attract biotech startups to emerging clusters in Lyon and Toulouse. The French healthcare system provides broad reimbursement coverage for advanced protein therapies, ensuring patient access and sustaining market demand. This strategic alignment of public funding, industrial policy, and scientific heritage positions France as a resilient and growing pillar of the European market.

Italy Protein Therapeutics Market Analysis

Italy is expected to be the most lucrative region in the European market during the forecast period, with a distinct focus on biosimilars and contract manufacturing. The market status is characterized by a thriving network of mid-sized pharmaceutical companies that specialize in producing cost-effective alternatives to off-patent biologic drugs, thereby increasing patient access across the continent. Italian manufacturers have invested heavily in single-use bioreactor technologies, which allow for flexible and efficient production of various protein formats, including enzymes and hormones. Recent reports show that Italy is one of the fastest-growing markets for biosimilars in Europe, with adoption rates increasing annually due to supportive pricing policies from the Italian Medicines Agency. The country serves as a key production hub for multinational corporations seeking to diversify their supply chains within the European Union. Strong academic centers in Milan and Rome collaborate with industry to optimize cell line development and purification processes, reducing production costs. The government has introduced specific decrees to streamline approval times for biosimilar products, encouraging competition and innovation. This strategic emphasis on affordability, manufacturing excellence, and regulatory support ensures Italy plays an increasingly important role in the broader European protein therapeutics ecosystem.

COMPETITIVE LANDSCAPE

The Europe protein therapeutics market features intense competition among multinational innovators, regional biosimilar manufacturers, and emerging biotech firms vying for dominance across therapeutic areas. Global leaders leverage integrated R&D, manufacturing, and commercial capabilities to maintain first-mover advantage in high-value indications like oncology and immunology. Meanwhile, biosimilar companies from Europe and Asia exert pricing pressure, particularly in mature segments such as anti-TNF and insulin therapies, forcing originators to differentiate through delivery devices, digital services, and real-world evidence. Regulatory harmonization under the European Medicines Agency facilitates centralized approval, but reimbursement remains fragmented, requiring tailored market access strategies per country. Innovation is increasingly concentrated in complex modalities, including bispecifics and fusion proteins, where technical barriers favor established players with legacy infrastructure. However, academic spin-outs supported by Horizon Europe funding are introducing novel protein scaffolds, challenging traditional paradigms. This dynamic interplay of scientific advancement, regulatory complexity, and health economic scrutiny defines a competitive landscape where clinical differentiation, operational excellence, and system integration determine sustained leadership.

KEY MARKET PLAYERS

The leading companies operating in the Europe protein therapeutics market include:

• Baxter International Inc.
• Eli Lilly and Company
• Abbott Laboratories
• Amgen Inc.
• Hoffmann-La Roche Ltd.
• Novo Nordisk A/S
• Pfizer Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• Sanofi

TOP PLAYERS IN THE MARKET

• Roche Holding AG, headquartered in Switzerland, is a global pioneer in protein therapeutics with a dominant presence across European oncology and immunology markets. The company’s portfolio includes landmark monoclonal antibodies such as trastuzumab, rituximab, and atezolizumab, which are embedded in national treatment guidelines throughout the EU. Roche has strengthened its position by expanding its biologics manufacturing capacity at its Basel facility to support next-generation antibody drug conjugates and bispecific formats. In 2024, the company launched a real-world evidence platform in collaboration with Germany’s AOK health insurer to track long-term outcomes of patients on its biologic therapies, enhancing value demonstration for payers. Its integrated diagnostics therapeutics strategy further enables biomarker-guided prescribing, reinforcing precision medicine adoption across European healthcare systems.
• Novo Nordisk A/S, based in Denmark, is a world leader in protein therapeutics for metabolic disorders, particularly insulin and GLP-1 analogs used in diabetes and obesity management. The company supplies over sixty percent of Europe’s insulin needs through a network of highly automated production sites in Kalundborg and Chartres. To reinforce its leadership, Novo Nordisk invested 1.2 billion euros in 2024 to expand fill-finish capacity for its next-generation insulin analogs and dual agonist proteins. It also partnered with the UK’s National Health Service to implement digital adherence tools that sync injection data with electronic health records, improving glycemic control monitoring. These initiatives underscore its commitment to combining therapeutic innovation with digital health integration to address Europe’s growing metabolic disease burden.
• Merck KGaA, headquartered in Germany, plays a critical role in the European protein therapeutics landscape through its EMD Serono division, which commercializes interferons, monoclonal antibodies, and fusion proteins for multiple sclerosis, cancer, and autoimmune diseases. The company co-developed avelumab, an anti-PD-L1 antibody now used in Merkel cell carcinoma and urothelial cancer across EU oncology centers. In 2024, Merck inaugurated a continuous bioprocessing pilot plant in Darmstadt, enabling faster, more flexible production of complex proteins with reduced footprint. It also launched a biosafety training academy for hospital pharmacists across Southern Europe to ensure proper handling and reconstitution of temperature-sensitive biologics. These actions reflect its dual focus on advanced manufacturing and healthcare system enablement to sustain therapeutic impact.

TOP STRATEGIES USED BY THE KEY MARKET PARTICIPANTS

Key players in the Europe protein therapeutics market pursue strategies centered on advanced manufacturing, real-world evidence generation, lifecycle management, and healthcare system integration. Companies are investing in continuous bioprocessing and AI-driven quality control to enhance yield and reduce costs while ensuring batch consistency. They actively collaborate with national health insurers and registries to generate real-world data demonstrating long-term clinical and economic value. Lifecycle innovation through next-generation formats such as bispecific antibody drug conjugates and half-life extended variants extends patent protection and therapeutic utility. Additionally, firms provide extensive training and digital support tools to healthcare professionals to ensure safe administration and patient adherence. Strategic partnerships with diagnostic companies further embed their therapies into precision medicine pathways, aligning treatment with biomarker status and payer requirements across diverse European healthcare systems.

EUROPE PROTEIN THERAPEUTICS MARKET NEWS

• In February 2024, Roche Holding AG expanded its Basel, Switzerland, biologics facility to increase production capacity for next-generation antibody drug conjugates targeting solid tumors in European oncology centers.
• In April 202,4 Novo Nordisk A/S committed 1.2 billion euros to upgrade its Kalundborg, Denmark, fill finish lines for dual agonist protein therapeutics addressing obesity and type 2 diabetes across EU markets.
• In June 2024, Merck KGaA launched a continuous bioprocessing pilot plant in Darmstadt, Germany, enabling flexible, rapid production of complex fusion proteins and monoclonal antibodies with reduced environmental footprint.
• In August 2024, Roche Holding AG initiated a real-world evidence partnership with Germany’s AOK health insurer to track five-year outcomes of patients receiving atezolizumab in non-small cell lung cancer treatment pathways.
• In October 2024, Novo Nordisk A/S rolled out a digital adherence platform across the UK National Health Service, linking insulin injection data to electronic health records to improve glycemic monitoring and clinical decision-making.

MARKET SEGMENTATION

This research report on the European protein therapeutics market has been segmented and sub-segmented into the following categories:

By Product

• Monoclonal Antibodies
• Insulin
• Fusion Protein
• Erythropoietin
• Interferon
• Human Growth Hormone
• Follicle Stimulating Hormone

By Application

• Metabolic Disorders
• Immunologic Disorders
• Hematological Disorders
• Cancer
• Hormonal Disorders
• Genetic Disorders
• Others

By Therapeutic Modalities

• Protein Diagnostics
• Protein Vaccines
• Protein Therapeutics with Special Targeting Activity
• Protein Therapeutics with Enzymatic Or Regulatory Activity

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe